Application status of non-invasive urine biopsy in diagnosis and recurrence surveillance of bladder cancer
10.3760/cma.j.cn115396-20231019-00095
- VernacularTitle:尿液无创检测在膀胱癌诊断和复发监测中的应用现状
- Author:
Hongchen SONG
1
;
Yufeng ZHANG
;
Menghua WU
;
Jiaxin LIU
;
Xuanhao LI
;
Jian SONG
;
Mingjun SHI
Author Information
1. 首都医科大学附属北京友谊医院泌尿外科，北京 100050
- Keywords:
Urinary bladder neoplasms;
Cytodiagnosis;
Recurrence;
Urine biopsy;
Biomarkers
- From:
International Journal of Surgery
2024;51(6):423-432
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer is one of the most common malignancy in the urinary system over the world. Urine cytology and cystoscopy are important tools for bladder cancer diagnosis and recurrence monitoring. However, due to the limited sensitivity and invasive procedure, there is an urgent need to develop new non-invasive and highly sensitive liquid biopsy approaches. Urine biopsy is a research focus in the field and has great potential. This review focused on protein-based urine markers (including NMP22, BTA and UroVysion etc.) and DNA or RNA-based urine markers (including cfDNA, AssureMDx and Xpert BC Monitor etc.), which were used for bladder cancer diagnosis and recurrence monitoring, and summarized the sensitivity and specificity of each biomarker as well as their characteristics in the diagnosis and recurrence surveillance of bladder cancer. This study provides theoretical and empirical support for further optimization and application of these biomarkers in clinical practice.
